These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11602685)

  • 1. Use of the beta-imager for rapid ex vivo autoradiography exemplified with central nervous system penetrating neurokinin 3 antagonists.
    Langlois X; te Riele P; Wintmolders C; Leysen JE; Jurzak M
    J Pharmacol Exp Ther; 2001 Nov; 299(2):712-7. PubMed ID: 11602685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular and behavioural effects of intracerebroventricularly administered tachykinin NK3 receptor antagonists in the conscious rat.
    Cellier E; Barbot L; Regoli D; Couture R
    Br J Pharmacol; 1997 Oct; 122(4):643-54. PubMed ID: 9375960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
    Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
    Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detailed distribution of Neurokinin 3 receptors in the rat, guinea pig and gerbil brain: a comparative autoradiographic study.
    Langlois X; Wintmolders C; te Riele P; Leysen JE; Jurzak M
    Neuropharmacology; 2001; 40(2):242-53. PubMed ID: 11114403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localization of Fos-like immunoreactivity induced by the NK3 tachykinin receptor agonist, senktide, in the guinea-pig brain.
    Yip J; Chahl LA
    Br J Pharmacol; 1997 Oct; 122(4):715-25. PubMed ID: 9375969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo characterization of NK3 receptors in the rabbit eye by use of selective non-peptide NK3 receptor antagonists.
    Medhurst AD; Hay DW; Parsons AA; Martin LD; Griswold DE
    Br J Pharmacol; 1997 Oct; 122(3):469-76. PubMed ID: 9351503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrophysiological, behavioural and biochemical evidence for activation of brain noradrenergic systems following neurokinin NK3 receptor stimulation.
    Jung M; Michaud JC; Steinberg R; Barnouin MC; Hayar A; Mons G; Souilhac J; Emonds-Alt X; Soubrié P; Le Fur G
    Neuroscience; 1996 Sep; 74(2):403-14. PubMed ID: 8865192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: biochemical and electrophysiological characterization.
    Malherbe P; Knoflach F; Marcuz A; Bohnert C; Weber M; Knust H; Ratni H; Spooren W; Ballard TM; Bissantz C
    Neuropharmacology; 2014 Nov; 86():259-72. PubMed ID: 25107588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of NK3 receptors in rabbit isolated iris sphincter muscle.
    Medhurst AD; Parsons AA; Roberts JC; Hay DW
    Br J Pharmacol; 1997 Jan; 120(1):93-101. PubMed ID: 9117105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the cloned human NK3 receptor in Chinese Hamster Ovary cells characterized by the cellular acidification response using the Cytosensor microphysiometer.
    Jordan RE; Smart D; Grimson P; Suman-Chauhan N; McKnight AT
    Br J Pharmacol; 1998 Oct; 125(4):761-6. PubMed ID: 9831912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of enhanced neurokinin NK3 receptor expression in the severe asthma guinea pig model.
    Mukaiyama O; Morimoto K; Nosaka E; Takahashi S; Yamashita M
    Eur J Pharmacol; 2004 Sep; 498(1-3):287-94. PubMed ID: 15364007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional characterization of the nonpeptide neurokinin3 (NK3) receptor antagonist, SR142801 on the human NK3 receptor expressed in Chinese hamster ovary cells.
    Oury-Donat F; Carayon P; Thurneyssen O; Pailhon V; Emonds-Alt X; Soubrié P; Le Fur G
    J Pharmacol Exp Ther; 1995 Jul; 274(1):148-54. PubMed ID: 7616392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig.
    Marco N; Thirion A; Mons G; Bougault I; Le Fur G; Soubrié P; Steinberg R
    Neuropeptides; 1998 Oct; 32(5):481-8. PubMed ID: 9845011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils.
    Nordquist RE; Durkin S; Jacquet A; Spooren W
    Eur J Pharmacol; 2008 Dec; 600(1-3):87-92. PubMed ID: 18930726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of neuronal NK1 and NK3 receptors in synaptic transmission during motility reflexes in the guinea-pig ileum.
    Johnson PJ; Bornstein JC; Burcher E
    Br J Pharmacol; 1998 Aug; 124(7):1375-84. PubMed ID: 9723948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for involvement of NK₃ receptors in the anxiogenic-like effect of SP6-11(C-terminal), a metabolite of substance P, in rats evaluated in the elevated plus-maze.
    Duarte FS; Duzzioni M; Leme LR; Smith Sde P; De Lima TC
    Behav Brain Res; 2016 Apr; 303():168-75. PubMed ID: 26851555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New quinoline NK3 receptor antagonists with CNS activity.
    Smith PW; Wyman PA; Lovell P; Goodacre C; Serafinowska HT; Vong A; Harrington F; Flynn S; Bradley DM; Porter R; Coggon S; Murkitt G; Searle K; Thomas DR; Watson JM; Martin W; Wu Z; Dawson LA
    Bioorg Med Chem Lett; 2009 Feb; 19(3):837-40. PubMed ID: 19117759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurokinin-3 peptide instead of neurokinin-1 synergistically exacerbates kainic acid-inducing degeneration of neurons in the substantia nigra of mice.
    Chen LW; Wang YQ; Bian GL; Wei LC; Yung KL
    J Neurochem; 2008 Apr; 105(1):203-16. PubMed ID: 18021294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
    Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
    J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia.
    Dawson LA; Cato KJ; Scott C; Watson JM; Wood MD; Foxton R; de la Flor R; Jones GA; Kew JN; Cluderay JE; Southam E; Murkitt GS; Gartlon J; Pemberton DJ; Jones DN; Davies CH; Hagan J
    Neuropsychopharmacology; 2008 Jun; 33(7):1642-52. PubMed ID: 17728699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.